PURE Bioscience Announces Approval to List on The NASDAQ Stock Market

SAN DIEGO--(Business Wire)--
PURE Bioscience (OTCBB: PURE) announced today that its application
for listing of its common stock has been approved by The NASDAQ Stock
Market. PURE Bioscience anticipates that its common stock will begin
trading on The NASDAQ Capital Market at the opening of the market on
Wednesday April 2, 2008. The stock will trade under the symbol "PURE."

"Returning to the NASDAQ Stock Market has been a primary goal for
us this year," said Michael L. Krall, President and Chief Executive
Officer of PURE Bioscience. "We expect NASDAQ's electronic multiple
market maker structure to provide our company with enhanced exposure
and liquidity, and afford our investors the best prices, the fastest
execution, and the lowest cost per trade. As the world's largest
electronic stock market, NASDAQ promotes innovation and attracts
leading growth companies from a diverse group of sectors. PURE
Bioscience certainly fits that description, and we look forward to
being a part of The NASDAQ Stock Market."

"We are thrilled that PURE Bioscience has chosen to relist their
stock on NASDAQ," said Bob McCooey, Senior Vice President of New
Listings and Capital Markets of The NASDAQ OMX Group, Inc. "PURE
Bioscience joins the world's largest exchange company that spans six
continents." We look forward to supporting PURE Bioscience and its
shareholders as they make their transition to NASDAQ."

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience
products that provide solutions to numerous global health challenges,
including Staph (MRSA). PURE's proprietary high efficacy/low toxicity
bioscience technologies, including its silver dihydrogen citrate-based
antimicrobials, represent innovative advances in diverse markets and
lead today's global trend toward industry and consumer use of "green"
products while providing competitive advantages in efficacy and
safety. Patented SDC is an electrolytically generated source of
stabilized ionic silver which formulates well with other compounds. As
a platform technology, SDC is distinguished from competitors in the
marketplace because of its superior efficacy, reduced toxicity and the
inability of bacteria to form a resistance to it. PURE is
headquartered in El Cajon, California (San Diego metropolitan area).
Additional information on PURE is available at www.purebio.com.

About NASDAQ(R)

The NASDAQ Stock Market, a national exchange owned and operated by
the NASDAQ OMX Group, Inc., is the largest U.S. electronic stock
market. With approximately 3,200 companies, it lists more companies
and, on average, its systems trade more shares per day than any other
U.S. market. NASDAQ is home to companies that are leaders across all
areas of business including technology, retail, communications,
financial services, transportation, media and biotechnology.

For more information about NASDAQ, visit the NASDAQ Web site at
www.nasdaq.com or the NASDAQ Newsroom(SM) at www.nasdaq.com/newsroom.

This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe",
"estimate", "project", "expect" or similar expressions. These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could cause
actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such differences
include, but are not limited to, acceptance of the Company's current
and future products and services in the marketplace, the ability of
the Company to develop effective new products and receive regulatory
approvals of such products, competitive factors, dependence upon
third-party vendors, and other risks detailed in the Company's
periodic report filings with the Securities and Exchange Commission.
By making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes after
the date of this release.

Investors:
Cameron Associates
Paul G. Henning, 212-554-5462
Vice President
paul@cameronassoc.com
or
Media:
Mentus
Karen Sparks, 858-455-5500 x 275
karen@mentus.com

Copyright Business Wire 2008